News | July 30, 2014

First Patient Enrolled in MASCOT Registry for Combo Dual-Therapy Stent

July 30, 2014 — OrbusNeich announced the first patient has been enrolled in the Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) post-marketing registry. The first Combo dual therapy stent implant was performed at the Amphia Hospital in Breda, The Netherlands.

Designed to assess the long-term safety and effectiveness of the Combo stent in routine clinical practice, the prospective, multicenter registry is the largest clinical study of the unique dual therapy stent to date, with a goal of 2,500 patients being followed for a year in up to 50 centers across Asia and Europe.

The study's primary endpoint is device-oriented target lesion failure (TLF), defined as the composite of cardiac death, non-fatal heart attack (myocardial infarction or MI) not clearly attributable to a non-target vessel, or target lesion revascularization (TLR) from enrollment to 12 months.

The principal investigator is Antonio Colombo, M.D., San Raffaele Hospital, Milan, Italy; the director of the clinical coordinating center is Roxana Mehran, M.D., Mount Sinai Medical Center.

"Long-term safety remains an important area of clinical investigation with stents, particularly the avoidance of neoatherosclerosis and late stent thrombosis," said Colombo. "The MASCOT registry will provide important information about the unique dual therapy approach of the Combo stent, which offers the possibility of functional arterial vessel healing, which we have not seen with any of the monotherapy drug-eluting stents."

"The clinical data gathered from Combo stent trials to date show promise with respect to long-term safety and efficacy," added Mehran. "For example, TLR remained stable at 5.7 percent in both years two and three of the REMEDEE trial, with no thrombotic events over three years. If those results hold in the MASCOT registry, that will be good news for patients and cardiologists."

OrbusNeich is supporting the Combo stent with a robust clinical program. In addition to the MASCOT registry, the REDUCE trial, which enrolled its first patient in June 2014, aims to demonstrate the potential for a shorter period of dual antiplatelet therapy.

"The initiation of MASCOT, our largest registry trial to date, represents the commitment we have made to really understand the patient benefits of the Combo stent," said B. Wayne Johnson, president and chief operating officer, OrbusNeich. "Only by delivering true vessel healing can patients feel safe for the long term. We expect the MASCOT trial to confirm what we have already seen with the Combo stent as it relates to vessel healing."

For more information: www.orbusneich.com

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init